<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500550</url>
  </required_header>
  <id_info>
    <org_study_id>CR-AIR-008</org_study_id>
    <nct_id>NCT02500550</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor</brief_title>
  <official_title>An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells (Using Photodynamic Treatment), in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiadis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiadis Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a repeat dose administration of ATIR101 is&#xD;
      safe and effective when infused in patients with a hematologic malignancy following a T-cell&#xD;
      depleted stem cell graft from a related haploidentical donor. All patients are planned to&#xD;
      receive two ATIR101 doses of 2×10E6 viable T-cells/kg, unless the second dose is reduced or&#xD;
      halted for safety reasons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study CR-AIR-008 is an exploratory, open-label, multicenter study. After signing informed&#xD;
      consent, patients will receive a hematopoietic stem cell transplantation (HSCT) from a&#xD;
      related, haploidentical donor, followed by a first ATIR101 infusion at a dose of 2×10E6&#xD;
      viable T-cells/kg between 28 and 32 days after the HSCT. Patients will receive a second&#xD;
      ATIR101 infusion at a dose of 2×10E6 viable T-cells/kg between 70 and 74 days after the HSCT.&#xD;
      To evaluate safety of the second dose administration, the first 6 patients treated will be&#xD;
      evaluated for the occurrence of dose limiting toxicity (DLT), defined as acute GvHD grade&#xD;
      III/IV within 120 days post HSCT (or within 42 days after the second ATIR101 infusion in case&#xD;
      of prior dose delays). If within the first 6 patients no DLT is observed, treatment of the&#xD;
      remaining 9 patients will continue with two ATIR101 doses of 2×10E6 viable T cells/kg. If&#xD;
      within the first 6 patients at least 2 patients show DLT, the second ATIR101 infusion will be&#xD;
      adjusted to a dose of 1×10E6 viable T cells/kg. If in one of the next 3 patients treated at&#xD;
      this lower dose again DLT is observed, the second ATIR101 infusion will be halted and the&#xD;
      remaining patients will be given only a single dose of ATIR101.&#xD;
&#xD;
      All patients treated with ATIR101 will be followed up until 12 months after the HSCT.&#xD;
      Assessments will be performed at weekly visits from the day of the first ATIR101 infusion&#xD;
      (Week 4) until 6 weeks after the second ATIR101 infusion (Week 16), at monthly visits from 4&#xD;
      until 6 months after the HSCT, and every 3 months from 6 until 12 months after the HSCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2015</start_date>
  <completion_date type="Actual">December 17, 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Acute Graft Versus Host Disease (GVHD) Grade III/IV</measure>
    <time_frame>180 days post HSCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Acute and Chronic GVHD</measure>
    <time_frame>Between 6 and 12 months after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved T-Cell Reconstitution at 6 and 12 Months Post HSCT</measure>
    <time_frame>6 and 12 months post HSCT</time_frame>
    <description>Defined as CD3+ in peripheral blood higher than 0.2×10E9/L at 6 and 12 months post HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral, Fungal, and Bacterial Infections</measure>
    <time_frame>From 6 months to 1 year after HSCT</time_frame>
    <description>Infection was defined as (1) a clinically apparent infectious disease with symptoms or (2) a viral reactivation. Severity was graded according to CTCAE vs. 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related Mortality (TRM)</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as death due to causes other than disease relapse or progression, or other causes which are unrelated to the transplantation procedure (e.g. accident, suicide)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-related Mortality (RRM)</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as death due to disease relapse or disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as the time from HSCT until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as the time from HSCT until relapse, disease progression, or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free, Relapse-free Survival (GRFS)</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as the time until acute GVHD grade III/IV, chronic GVHD requiring systemic treatment, relapse, or death, whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>ATIR101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATIR101</intervention_name>
    <description>T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).</description>
    <arm_group_label>ATIR101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Haploidentical hematopoietic stem cell transplantation (HSCT)</intervention_name>
    <description>CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)</description>
    <arm_group_label>ATIR101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TBI regime</intervention_name>
    <description>Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
    <arm_group_label>ATIR101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Non-TBI regime</intervention_name>
    <description>Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
    <arm_group_label>ATIR101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any of the following hematologic malignancies:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) in first remission with high-risk features or in&#xD;
                  second or higher remission&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL) in first remission with high-risk features or&#xD;
                  in second or higher remission&#xD;
&#xD;
               -  Myelodysplastic syndrome (MDS): transfusion-dependent, or intermediate or higher&#xD;
                  IPSS-R risk group&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70%&#xD;
&#xD;
          -  Eligible for haploidentical stem cell transplantation according to the investigator&#xD;
&#xD;
          -  Male or female, age ≥ 18 years and ≤ 65 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Availability of a fully matched related or unrelated donor following a donor search&#xD;
&#xD;
          -  Diffusing capacity for carbon monoxide (DLCO) &lt; 50% predicted&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50% (evaluated by echocardiogram or MUGA)&#xD;
&#xD;
          -  AST &gt; 2.5 x ULN (CTCAE grade 2)&#xD;
&#xD;
          -  Bilirubin &gt; 1.5 x ULN (CTCAE grade 2)&#xD;
&#xD;
          -  Creatinine clearance &lt; 50 mL/min (calculated or measured)&#xD;
&#xD;
          -  Positive HIV test&#xD;
&#xD;
          -  Positive pregnancy test (women of childbearing age only)&#xD;
&#xD;
          -  Prior allogeneic HSCT&#xD;
&#xD;
          -  Estimated probability of surviving less than 3 months&#xD;
&#xD;
          -  Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)&#xD;
&#xD;
          -  Known presence of HLA antibodies against the non-shared donor haplotype&#xD;
&#xD;
          -  Any other condition which, in the opinion of the investigator, makes the patient&#xD;
             ineligible for the study&#xD;
&#xD;
        Inclusion Criteria Donor:&#xD;
&#xD;
          -  Haploidentical family donor with 2 to 3 mismatches at the HLA-A, -B and/or -DR loci of&#xD;
             the unshared haplotype&#xD;
&#xD;
          -  Male or female, age ≥ 16 and ≤ 75 years (If applicable, local legal requirements for&#xD;
             donors under the age of 18 will be followed)&#xD;
&#xD;
          -  Eligible for donations of human blood and blood components according to local&#xD;
             requirements and regulations&#xD;
&#xD;
          -  Eligible for donation according to the transplantation center&#xD;
&#xD;
        Exclusion Criteria Donor:&#xD;
&#xD;
          -  Positive pregnancy test or nursing (women of childbearing age only)&#xD;
&#xD;
          -  Positive viral test for HIV-1, HIV-2, HBV, HCV, Treponema pallidum, HTLV 1 (if&#xD;
             tested), HTLV-2 (if tested), or WNV (if tested)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Claude Roy, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital (Montreal, Canada)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Mielke, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital (Stockholm, Sweden)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital and Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria, Clinica Universitaria Hematologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 ONN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 14, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <results_first_submitted>December 17, 2020</results_first_submitted>
  <results_first_submitted_qc>December 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2021</results_first_posted>
  <disposition_first_submitted>August 19, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 19, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 20, 2019</disposition_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haploidentical stem cell transplantation</keyword>
  <keyword>Graft versus host disease</keyword>
  <keyword>Immune reconstitution</keyword>
  <keyword>Alloreactive T-cells</keyword>
  <keyword>Photodynamic treatment</keyword>
  <keyword>Hematologic malignancy</keyword>
  <keyword>Transplant-related mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02500550/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02500550/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ATIR101</title>
          <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ATIR101</title>
          <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="15" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Acute Graft Versus Host Disease (GVHD) Grade III/IV</title>
        <time_frame>180 days post HSCT</time_frame>
        <population>The primary study endpoint, grade III/IV acute GVHD within 180 days after HSCT, was met for two patients treated with two doses of ATIR101.&#xD;
Two patients developed grade III/IV acute GVHD within 180 days after HSCT treated with a single dose of ATIR101.</population>
        <group_list>
          <group group_id="O1">
            <title>ATIR101</title>
            <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Graft Versus Host Disease (GVHD) Grade III/IV</title>
          <population>The primary study endpoint, grade III/IV acute GVHD within 180 days after HSCT, was met for two patients treated with two doses of ATIR101.&#xD;
Two patients developed grade III/IV acute GVHD within 180 days after HSCT treated with a single dose of ATIR101.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose of ATIR101, grade III/IV acute GVHD within 180 days after HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two doses of ATIR101, Grade III/IV acute GVHD within 180 days after HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Severity of Acute and Chronic GVHD</title>
        <time_frame>Between 6 and 12 months after HSCT</time_frame>
        <population>7 patients in the single dose and 4 patients in the double dose were analysed to make a total of 11 patients analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>ATIR101</title>
            <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Acute and Chronic GVHD</title>
          <population>7 patients in the single dose and 4 patients in the double dose were analysed to make a total of 11 patients analysed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose group acute GVHD between 6 and 12 months after HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double dose group acute GVHD between 6 and 12 months after HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single dose group chronic GVHD between 6 and 12 months after HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double dose group chronic GVHD between 6 and 12 months after HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved T-Cell Reconstitution at 6 and 12 Months Post HSCT</title>
        <description>Defined as CD3+ in peripheral blood higher than 0.2×10E9/L at 6 and 12 months post HSCT.</description>
        <time_frame>6 and 12 months post HSCT</time_frame>
        <population>Cumulative incidence estimates of T-cell reconstitution at 6 and 12 months post HSCT were analyzed for the single dose group (N=9) and double dose group (N=6).</population>
        <group_list>
          <group group_id="O1">
            <title>ATIR101</title>
            <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved T-Cell Reconstitution at 6 and 12 Months Post HSCT</title>
          <description>Defined as CD3+ in peripheral blood higher than 0.2×10E9/L at 6 and 12 months post HSCT.</description>
          <population>Cumulative incidence estimates of T-cell reconstitution at 6 and 12 months post HSCT were analyzed for the single dose group (N=9) and double dose group (N=6).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cumulative incidence estimates of T-cell reconstitution, 6 months post HSCT. Single dose group.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="11.0" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence estimates of T-cell reconstitution, 6 months post HSCT. Double dose group.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="8.2" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence estimates of T-cell reconstitution, 12 months post HSCT. Single dose group.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="32.7" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence estimates of T-cell reconstitution, 12 months post HSCT. Double dose group.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="8.2" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral, Fungal, and Bacterial Infections</title>
        <description>Infection was defined as (1) a clinically apparent infectious disease with symptoms or (2) a viral reactivation. Severity was graded according to CTCAE vs. 4.0</description>
        <time_frame>From 6 months to 1 year after HSCT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ATIR101</title>
            <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral, Fungal, and Bacterial Infections</title>
          <description>Infection was defined as (1) a clinically apparent infectious disease with symptoms or (2) a viral reactivation. Severity was graded according to CTCAE vs. 4.0</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity, grade 1-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity, grade 3-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplant-related Mortality (TRM)</title>
        <description>Defined as death due to causes other than disease relapse or progression, or other causes which are unrelated to the transplantation procedure (e.g. accident, suicide)</description>
        <time_frame>12 months post HSCT</time_frame>
        <population>Nine participants received a single dose of ATIR101 and 6 participants received a double dose of ATIR101</population>
        <group_list>
          <group group_id="O1">
            <title>ATIR101</title>
            <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant-related Mortality (TRM)</title>
          <description>Defined as death due to causes other than disease relapse or progression, or other causes which are unrelated to the transplantation procedure (e.g. accident, suicide)</description>
          <population>Nine participants received a single dose of ATIR101 and 6 participants received a double dose of ATIR101</population>
          <units>percentage of participants that died</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single-dose group, cumulative estimates of TRM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="2.8" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-dose group, cumulative estimates of TRM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="12.2" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse-related Mortality (RRM)</title>
        <description>Defined as death due to disease relapse or disease progression</description>
        <time_frame>12 months post HSCT</time_frame>
        <population>Nine participants received a single dose of ATIR101 and 6 participants received a double dose of ATIR101</population>
        <group_list>
          <group group_id="O1">
            <title>ATIR101</title>
            <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse-related Mortality (RRM)</title>
          <description>Defined as death due to disease relapse or disease progression</description>
          <population>Nine participants received a single dose of ATIR101 and 6 participants received a double dose of ATIR101</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose group, cumulative estimates of RRM 12 months post HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="0.5" upper_limit="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double dose group, cumulative estimates of RRM 12 months post HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Defined as the time from HSCT until death from any cause</description>
        <time_frame>12 months post HSCT</time_frame>
        <population>Nine participants received a single dose of ATIR101 and 6 participants received a double dose of ATIR101</population>
        <group_list>
          <group group_id="O1">
            <title>ATIR101</title>
            <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Defined as the time from HSCT until death from any cause</description>
          <population>Nine participants received a single dose of ATIR101 and 6 participants received a double dose of ATIR101</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose group, Kaplan-Meier estimates of OS 12 months post HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="28.2" upper_limit="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double dose group, Kaplan-Meier estimates of OS 12 months post HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="4.6" upper_limit="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Defined as the time from HSCT until relapse, disease progression, or death, whichever occurs first</description>
        <time_frame>12 months post HSCT</time_frame>
        <population>Nine participants received a single dose of ATIR101 and 6 participants received a double dose of ATIR101</population>
        <group_list>
          <group group_id="O1">
            <title>ATIR101</title>
            <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Defined as the time from HSCT until relapse, disease progression, or death, whichever occurs first</description>
          <population>Nine participants received a single dose of ATIR101 and 6 participants received a double dose of ATIR101</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose group, Kaplan-Meier estimates of PFS 12 months post HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="20.4" upper_limit="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double dose group, Kaplan-Meier estimates of PFS 12 months post HSCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="4.6" upper_limit="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GVHD-free, Relapse-free Survival (GRFS)</title>
        <description>Defined as the time until acute GVHD grade III/IV, chronic GVHD requiring systemic treatment, relapse, or death, whichever occurs first</description>
        <time_frame>12 months post HSCT</time_frame>
        <population>Nine subjects received a single dose of ATIR101 and 6 subjects received a double dose of ATIR101.</population>
        <group_list>
          <group group_id="O1">
            <title>ATIR101</title>
            <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
          </group>
        </group_list>
        <measure>
          <title>GVHD-free, Relapse-free Survival (GRFS)</title>
          <description>Defined as the time until acute GVHD grade III/IV, chronic GVHD requiring systemic treatment, relapse, or death, whichever occurs first</description>
          <population>Nine subjects received a single dose of ATIR101 and 6 subjects received a double dose of ATIR101.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose, Kaplan-Meier estimates of GRFS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="20.4" upper_limit="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double dose, Kaplan-Meier estimates of GRFS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="0.8" upper_limit="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The median follow-up time of ATIR101-treated patients in the study was 11.6 (range 2.7-12.8) months after hematopoietic stem cell transplantation (HSCT) .</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ATIR101</title>
          <description>ATIR101: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).&#xD;
Haploidentical hematopoietic stem cell transplantation (HSCT): CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:&#xD;
Total Body Irradiation (TBI) regime&#xD;
Non-TBI regime&#xD;
(See below for details)&#xD;
TBI regime: • Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)&#xD;
Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.&#xD;
Non-TBI regime: • Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4&#xD;
Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7&#xD;
Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1&#xD;
ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft-versus-host disease (GVHD)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chronic GVHD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute GVHD</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chronic GVHD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus (CMV) positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Sandler, MD / Chief Medical Officer</name_or_title>
      <organization>Kiadis Pharma Netherlands B.V.</organization>
      <phone>+1 206 779 9213</phone>
      <email>a.sandler@kiadis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

